ArticleScientific data2022
Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort.
Open access · goldAbstract readDataset
In one paragraph
Article in Scientific data, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.6field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Two faces of drug repurposing data in machine learning-driven structure-based virtual screening supported by interaction fingerprints.Journal of computer-aided molecular design · 2026Article
- Experimental and machine learning-based exploration of repurposed drugs reveals chemical features underlying phospholipidosis.Patterns (New York, N.Y.) · 2026Article
- Integrated UHPLC-QTOF-MS, Network Pharmacology, and Experimental Validation Reveal the Antiviral and Anti-Inflammatory Mechanisms of Xiaoer Fengreqing Against COVID-19-Associated Encephalitis.Infection and drug resistance · 2026Article
- Dual-Site Inhibition of SARS-CoV-2 RNA-Dependent RNA Polymerase by Small Molecules Able to Block Viral Replication Identified through a Computer-Aided Drug Discovery Approach.ACS infectious diseases · 2025Article
- Optimization and Evaluation of Complementary Degrader Discovery Assays for Application in Screening.ACS pharmacology & translational science · 2025Article
- Identification, validation, and characterization of approved and investigational drugs interfering with the SARS-CoV-2 endoribonuclease Nsp15.Protein science : a publication of the Protein Society · 2025Article
- PBPK-led assessment of antimalarial drugs as candidates for Covid-19: Simulating concentrations at the site of action to inform repurposing strategies.Clinical and translational science · 2024Article
- Drug repurposing screen to identify inhibitors of the RNA polymerase (nsp12) and helicase (nsp13) from SARS-CoV-2 replication and transcription complex.Virus research · 2024Article
- Multiplexed multicolor antiviral assay amenable for high-throughput research.Nature communications · 2024Article
- Target Prediction by Multiple Virtual Screenings: Analyzing the SARS-CoV-2 Phenotypic Screening by the Docking Simulations Submitted to the MEDIATE Initiative.International journal of molecular sciences · 2023Article
- DeepCoVDR: deep transfer learning with graph transformer and cross-attention for predicting COVID-19 drug response.Bioinformatics (Oxford, England) · 2023Article
- Identification of small molecules capable of enhancing viral membrane fusion.Virology journal · 2023Article
- DHFR Inhibitors Display a Pleiotropic Anti-Viral Activity against SARS-CoV-2: Insights into the Mechanisms of Action.Viruses · 2023Article
- Alliance of Heart and Endoderm: Multilineage Organoids to Model Co-development.Circulation research · 2023Review
- Effects of Usnic Acid to Prevent Infections by Creating a Protective Barrier in an In Vitro Study.International journal of molecular sciences · 2023Article
- Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery.Antiviral research · 2023Article
- A potential role for SARS-CoV-2 small viral RNAs in targeting host microRNAs and modulating gene expression.Scientific reports · 2022Article
- Article
- Systematic Down-Selection of Repurposed Drug Candidates for COVID-19.International journal of molecular sciences · 2022Article
- Exscalate4CoV: Innovative High Performing Computing (HPC) Strategies to Tackle Pandemic Crisis.International journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 6 institutions in 3 countries.
Andrea ZalianiFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, Schnackenburgallee 114, 22525, Hamburg, Germany. andrea.zaliani@itmp.fraunhofer.de.
Laura VangeelKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium.ORCID 0000-0001-8820-6617
Jeanette ReinshagenFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, Schnackenburgallee 114, 22525, Hamburg, Germany.
Daniela IaconisDompé Farmaceutici SpA, via Campo di Pile, 67100, L'Aquila, Italy.ORCID 0000-0002-1052-6634
Maria KuzikovFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, Schnackenburgallee 114, 22525, Hamburg, Germany.
Oliver KeminerFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, Schnackenburgallee 114, 22525, Hamburg, Germany.
Markus WolfFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, Schnackenburgallee 114, 22525, Hamburg, Germany.
Bernhard EllingerFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, Schnackenburgallee 114, 22525, Hamburg, Germany.
Francesca EspositoDipartimento di Scienze della vita e dell'ambiente, Cittadella Universitaria di Monserrato, SS554, 09042, Monserrato, Cagliari, Italy.
Angela CoronaDipartimento di Scienze della vita e dell'ambiente, Cittadella Universitaria di Monserrato, SS554, 09042, Monserrato, Cagliari, Italy.ORCID 0000-0002-6630-8636
Enzo TramontanoDipartimento di Scienze della vita e dell'ambiente, Cittadella Universitaria di Monserrato, SS554, 09042, Monserrato, Cagliari, Italy.ORCID 0000-0002-4849-0980
Candida ManelfiDompé Farmaceutici SpA, via Campo di Pile, 67100, L'Aquila, Italy.
Katja HerzogEU-OPENSCREEN ERIC, Campus Berlin Buch, Robert-Rössle-Str. 10, 13125, Berlin, Germany.
Dirk JochmansKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium.ORCID 0000-0002-9265-6028
Steven De JongheKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium.ORCID 0000-0002-3872-6558
Winston ChiuKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium.ORCID 0000-0001-5236-623X
Thibault FranckenKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium.
Joost SchepersKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium.
Caroline CollardKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium.
Kayvan AbbasiKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium.
Carsten ClaussenFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, Schnackenburgallee 114, 22525, Hamburg, Germany.
Vincenzo SummaDepartment of Excellence of Pharmacy, University of Naples Federico II, Via D. Montesano, 49, 80131, Naples, Italy.
Andrea R BeccariDompé Farmaceutici SpA, via Campo di Pile, 67100, L'Aquila, Italy.
Johan NeytsKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium.ORCID 0000-0002-0033-7514
Philip GribbonFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Discovery Research ScreeningPort, Schnackenburgallee 114, 22525, Hamburg, Germany.
Pieter LeyssenKU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Herestraat 49 - box 1043, 3000, Leuven, Belgium.ORCID 0000-0002-7537-1688
Rega Institute for Medical Research · BEMerck (Germany) · DEDompé (Italy) · ITIstituto Nazionale di Fisica Nucleare, Sezione di Cagliari · ITFraunhofer Institute for Translational Medicine and Pharmacology · DEUniversity of Naples Federico II · IT
Funding
EC | EU Framework Programme for Research and Innovation H2020 | H2020 Excellent Science (H2020 Priority Excellent Science) 101003551
Abstract
Worldwide, there are intensive efforts to identify repurposed drugs as potential therapies against SARS-CoV-2 infection and the associated COVID-19 disease. To date, the anti-inflammatory drug dexamethasone and (to a lesser extent) the RNA-polymerase inhibitor remdesivir have been shown to be effective in reducing mortality and patient time to recovery, respectively, in patients. Here, we report the results of a phenotypic screening campaign within an EU-funded project (H2020-EXSCALATE4COV) aimed at extending the repertoire of anti-COVID therapeutics through repurposing of available compounds and highlighting compounds with new mechanisms of action against viral infection. We screened 8702 molecules from different repurposing libraries, to reveal 110 compounds with an anti-cytopathic IC
Indexed as
COVID-19 Drug TreatmentSARS-CoV-2Antiviral AgentsDrug DiscoveryDrug RepositioningHumansAntiviral Agents
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.